Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
ISCHAEMIC HEART DISEASE
Low molecular weight heparin to treat pulmonary embolism ▸ In a meta-analysis of 12 trials, low molecular weight heparin was associated with a non-significant decrease in recurrent symptomatic venous thromboembolism at the end of treatment (1.4% v 2.4%; odds ratio (OR) 0.63, 95% confidence interval (CI) 0.33 to 1.18) and at three months (3.0% v 4.4%; OR 0.68, 95% CI 0.42 to 1.09) compared to unfractionated heparin. Similar estimates were obtained for patients who presented with symptomatic pulmonary embolism (1.7% v 2.3%; OR 0.72, 95% CI 0.35 to 1.48) or asymptomatic pulmonary embolism (1.2% v 3.2%; OR 0.53, 95% CI 0.15 to 1.88). For major bleeding complications, the odds ratio favouring low molecular weight heparin (1.3% v 2.1%; OR 0.67, 95% CI 0.36 to 1.27) was also not significant. This suggests that low molecular weight heparin is probably a safer alternative for the treatment of pulmonary as well as deep vein thrombosis.
Warfarin for six months removes atrial appendage thrombus in 25% ▸ Among 219 candidates for percutaneous mitral commissurotomy (PTMC) with left atrial thrombus (mean age 39.6 (7.4) years) complete resolution of thrombus was demonstrated in 53 patients (24.2%), who subsequently underwent successful PTMC. In another 166 patients, the thrombus size was reduced by 24% (p < 0.001). No thrombus resolution was observed in the 27 patients with a left atrial body thrombus. Eighteen patients had minor bleeding. The significant predictors of thrombus resolution were a New York Heart Association functional class ⩽ II, a left atrial appendage thrombus size ⩽ 1.6 cm2, a left atrial spontaneous echocardiographic contrast grade of ⩽ 1, and an international normalised ratio (INR) of at least 2.5. Patients with all of these predictors had a 94.4% chance of complete thrombus resolution (95% CI 84.4% to 98.1%).
Chest pain clinics are effective as well as being a government demand ▸ The emergency room of a large hospital sees a lot of chest pain patients. Sorting the wheat from the chaff is easier with troponin measurements, but is still a problem. In 972 patients, half attended on days when a chest pain unit was in use, and half when standard care was given. Use of a chest pain observation unit reduced the proportion of patients admitted from 54% to 37% (difference 17%; OR 0.50, 95% CI 0.39 to 0.65, p < 0.001) and the proportion discharged with acute coronary syndrome from 14% to 6% (OR 8%, 95% CI −7% to 23%, p = 0.264). Rates of cardiac event were unchanged. Care in the chest pain observation unit was associated with a saving of £78 per patient (95% CI −£56 to £210, p = 0.252).
Placental growth factor as a marker for risk above and beyond the troponin level ▸ Concentrations of placental growth factor (PlGF) as well as concentrations of markers of myocardial necrosis (troponin T), platelet activation (soluble CD40 ligand), and inflammation (high sensitivity C reactive protein (hsCRP)) were measured in 547 patients with angiographically validated acute coronary syndrome (ACS) participating in the CAPTURE (c7E3 Fab anti-platelet therapy in unstable refractory angina) trial and in a heterogeneous cohort of 626 patients presenting with acute chest pain to an emergency department in Germany between December 1996 and March 1999. In patients with ACS, elevated PlGF values (> 27.0 ng/l; 40.8% of patients) indicated a notably increased risk of events at 30 days (14.8% v 4.9%, p < 0.001). In a multivariable model, elevated values of TnT, sCD40L, and PlGF (hazard ratio (HR) 3.03, 95% CI 1.54 to 5.95, p < 0.001) were independent predictors, while elevated hsCRP concentration was not. In patients with acute chest pain, elevated concentrations of PlGF predicted risk (21.2% v 5.3%) (unadjusted: HR 4.80, 95% CI 2.81 to 8.21, p < 0.001; adjusted: HR 3.00, 95% CI 1.68 to 5.38, p < 0.001). Patients negative for all three markers (TnT, sCD40L, and PlGF) were at very low cardiac risk (7 days: no event; 30 days: 2.1% event rate).
Ranolazine: the new antianginal ▸ The antianginal action of ranolazine may be related to partial inhibition of fatty acid oxidation, which can produce anti-ischaemic effects without depressing haemodynamic function. Inhibition of fatty acid oxidation reciprocally increases glucose oxidation, which generates more adenosine triphosphate for each molecule of oxygen consumed. This shift in substrate selection may reduce myocardial oxygen supply needed to support a given level of cardiac work so that for any level of coronary flow, ischaemia should be less likely. Trough exercise duration increased by 115.6 seconds from baseline in both ranolazine groups (pooled) versus 91.7 seconds in the placebo group (p = 0.01). The times to angina and to electrocardiographic ischaemia also increased in the ranolazine groups, at peak more than at trough. The increases did not depend on changes in blood pressure, heart rate, or background antianginal treatment and persisted throughout 12 weeks. Ranolazine reduced angina attacks and glyceryl trinitrate use by about one per week versus placebo (p < 0.02). There was no difference in survival or cardiovascular events in the two groups.
Exercise training in heart failure saves lives: a meta-analysis ▸ In health taking more exercise is associated with better prognosis; the same should hold true when you are not healthy. Single studies of exercise in heart failure have not been powered to show reduced mortality. This meta-analysis suggests mortality was significantly lower in the exercise group (log rank χ2 = 5.9, p = 0.015). The hazard ratio for mortality was computed to be 0.65 (95% CI 0.46 to 0.92). These results imply a number needed to treat of 17 to prevent one death in two years. This effect was not explained by any difference in drug regimen.
Checking blood pressure every six months is as good as every three months ▸ How often should the general practitioner check your blood pressure? Most guidelines suggest 3–6 months once control is achieved. A total of 302 patients were randomly assigned to follow up every three months and 307 to follow up every six months. As expected, patients in the six month group had significantly fewer visits, but patients in both groups visited their doctor more frequently than their assigned interval. Mean blood pressure was similar in the groups, as was control of hypertension. Patient satisfaction and adherence to treatment were similar in the groups. About 20% of patients in each group had blood pressures that were out of control during the study.
American Journal of Medicine; American Journal of Physiology: Heart and Circulatory Physiology; Annals of Emergency Medicine; Annals of Thoracic Surgery; Archives of Internal Medicine; BMJ; Chest; European Journal of Cardiothoracic Surgery; Lancet; JAMA; Journal of Clinical Investigation; Journal of Diabetes and its Complications; Journal of Immunology; Journal of Thoracic and Cardiovascular Surgery; Nature Medicine; New England Journal of Medicine; Pharmacoeconomics; Thorax
Dr Diana Gorog, Dr Akhil Kapur, Dr Masood Khan, Dr Alistair Lindsay, Dr Andrew Sharp